Evexia Lifecare Ltd (EVEXIA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Evexia Lifecare Ltd stock ₹0.19, price ₹1.46, that is 87.0% below the price, quality 34 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range ₹0.4900 – ₹11.66 · fair‑value band ₹0.1400 – ₹0.2400 · the ₹1.46 price screens above the ₹0.1900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Evexia Lifecare in your weekly email
Every Wednesday you see whether Evexia Lifecare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Evexia Lifecare Ltd (EVEXIA) currently trades at ₹1.46, while our model-based Fair Value estimate is ₹0.1900, 87% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ₹1.46 per share, and 1 of the 14 models we run sit above the ₹1.46 price.
Bear case: the Earnings-Based group reads lowest at ₹0.1700, and 13 of the 14 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹0.1400 (bear) to ₹0.2400 (bull), the price of ₹1.46 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Health Care sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Evexia Lifecare Ltd reported revenue of ₹1.1B in FY2026 versus ₹755M in FY2022, a compound +9.9%/yr. Reported net income was ₹16.2M in FY2026, compounding +17.1%/yr from FY2022.
Key figures
Market cap ₹2.7B (≈ $29.2M) Micro · P/E ratio 146.0 · P/S ratio 1.42 · EPS (TTM) ₹0.0100 · Net margin 1.0% · Return on equity 0.3% · Return on assets (EBIT) 0.5% (5-year average) · Operating margin 1.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (medium confidence).
What moves the price
The share trades about 35% below its 52-week high and 198% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −16% fair-value upside, at −87%, EVEXIA screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹0.0800 to ₹9.78). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear₹0.1400Fair Value ₹0.1900Bull₹0.2400
Price ₹1.46 · Downside -87.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹0.0061 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.26/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+27.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Start year 2021 (pandemic)
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−13.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−13.0%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 2%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 54 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score34 · Bottom 25%
Fair Value upside−87.0% · Bottom 25%
Profitability
Return on equity (12 months)0.3% · Below median
Return on assets0.2% · Below median
Net margin (12 months)1.0% · Below median
Operating margin (12 months)1.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)39.8% · Top 25%
Balance sheet
Debt / equity0.00× · Below median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
P/E (12 months)146.0× · Priciest 25%
P/B0.63× · Cheaper than median
P/S (12 months)2.43× · Priciest 25%
EV/EBITDA55.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 51
PAST (return on equity)1· sector 15
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 26
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Evexia Lifecare Ltd (EVEXIA) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ₹0.1900 versus a price of ₹1.46, about 87% lower (overvalued).
What is the fair value of EVEXIA?
Our model-based fair value for Evexia Lifecare Ltd is ₹0.1900 (as of Nov 5, 2026), built from audited fundamentals. The current price: ₹1.46.
What is the quality score of EVEXIA?
Evexia Lifecare Ltd has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evexia Lifecare Ltd (EVEXIA)?
Our model-based price target is the fair value of ₹0.1900 (as of Nov 5, 2026) from 14 valuation models. Cautious scenario ₹0.1400, optimistic scenario ₹0.2400. It is a calculation from audited fundamentals, not an analyst target.
What is the Evexia Lifecare Ltd stock forecast for 2026?
Our models put fair value at ₹0.1900, about 87% lower versus a price of ₹1.46 (overvalued). Cautious scenario ₹0.1400, optimistic scenario ₹0.2400. The calculation is refreshed regularly with new filings.
What is the revenue of Evexia Lifecare Ltd (EVEXIA)?
Evexia Lifecare Ltd reported trailing-twelve-month revenue of about ₹1.1B (latest available figure, as of Nov 5, 2026).
What is the intrinsic value of Evexia Lifecare Ltd (EVEXIA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evexia Lifecare Ltd it is ₹0.1900 per share (as of Nov 5, 2026), against a price of ₹1.46. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Evexia Lifecare Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, EVEXIA trades above its calculated fair value: price ₹1.46, fair value ₹0.1900, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EVEXIA?
No. The price is what the market pays today (₹1.46); the fair value is what the company's own numbers justify (₹0.1900). For Evexia Lifecare Ltd the two are ₹1.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evexia Lifecare Ltd worth?
The market values Evexia Lifecare Ltd at about ₹2.7B (market capitalisation, as of Nov 5, 2026). Per share that is ₹1.46; our models calculate a fair value of ₹0.1900 per share.
What do the bullish and bearish scenarios say about EVEXIA?
Our models span a range for Evexia Lifecare Ltd: cautious scenario ₹0.1400, base ₹0.1900, optimistic ₹0.2400 per share (as of Nov 5, 2026, price ₹1.46). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EVEXIA?
Evexia Lifecare Ltd trades at a price-to-earnings ratio of 146.0 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹0.1900 is built from several models across several years. Other multiples: P/B 0.6, P/S 2.4, EV/EBITDA 55.9.
How solid is the balance sheet of Evexia Lifecare Ltd (EVEXIA)?
Balance-sheet figures for Evexia Lifecare Ltd (as of Nov 5, 2026): return on equity 0.3%, debt of 0.00 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is EVEXIA from its 52-week high?
Evexia Lifecare Ltd trades at ₹1.46, about 35% below its 52-week high of ₹2.24 and 198% above the low of ₹0.4900 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ₹0.1900 is for.
Which stocks are comparable to Evexia Lifecare Ltd?
From the same area (Health Care) we also value ST Pharm Co, Caregen Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evexia Lifecare Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price ₹1.46, calculated fair value ₹0.1900 (−87%), Quality Score 34/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EVEXIA calculated?
We run Evexia Lifecare Ltd through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹0.1900 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Evexia Lifecare Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evexia Lifecare Ltd (EVEXIA)?
The closing price on Nov 6, 2026 was ₹1.46. Our model-based fair value is ₹0.1900, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evexia Lifecare Ltd right now?
The price sits above even our optimistic bull case (₹0.2400). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Evexia Lifecare Ltd
How large is the market capitalisation of Evexia Lifecare Ltd (EVEXIA)?
The market capitalisation of Evexia Lifecare Ltd is ₹2.7B (≈ $29.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Evexia Lifecare Ltd (EVEXIA)?
The price-to-sales ratio of Evexia Lifecare Ltd is 1.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Evexia Lifecare Ltd (EVEXIA)?
Earnings per share at Evexia Lifecare Ltd are ₹0.0100 (price ÷ EPS = P/E 146.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Evexia Lifecare Ltd (EVEXIA)?
The net margin of Evexia Lifecare Ltd is 1.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Evexia Lifecare Ltd (EVEXIA)?
The return on equity (ROE) of Evexia Lifecare Ltd is 0.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evexia Lifecare Ltd (EVEXIA)?
On an EBIT basis the return on assets of Evexia Lifecare Ltd is 0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evexia Lifecare Ltd (EVEXIA)?
The operating margin of Evexia Lifecare Ltd is 1.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Evexia Lifecare Ltd (EVEXIA)?
Revenue at Evexia Lifecare Ltd is growing +39.8% versus a year earlier (3y avg +16.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Evexia Lifecare Ltd (EVEXIA)?
Earnings per share at Evexia Lifecare Ltd are growing +157% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Evexia Lifecare Ltd (EVEXIA) generate?
The free cash flow of Evexia Lifecare Ltd is −₹267M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Evexia Lifecare Ltd (EVEXIA) carry?
The net debt of Evexia Lifecare Ltd is ₹5.0M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Evexia Lifecare Ltd in the live analysis
One click puts Evexia Lifecare Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026